Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins

Multiple drug resistance (MDR) in bacterial infections is developed with the abuse of antibiotics, posing a severe threat to global health. Tedizolid phosphate (TR-701) is an efficient prodrug of tedizolid (TR-700) against gram-positive bacteria, including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). Herein, a novel drug delivery system: Red blood cell membrane (RBCM) coated TR-701-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles (RBCM-PLGA-TR-701NPs, RPTR-701Ns) was proposed. The RPTR-701Ns possessed a double-layer core-shell structure with 192.50 ± 5.85 nm in size, an average encapsulation efficiency of 36.63% and a 48 h-sustained release in vitro. Superior bio-compatibility was confirmed with red blood cells (RBCs) and HEK 293 cells. Due to the RBCM coating, RPTR-701Ns on one hand significantly reduced phagocytosis by RAW 264.7 cells as compared to PTR-701Ns, showing an immune escape effect. On the other hand, RPTR-701Ns had an advanced exotoxins neutralization ability, which helped reduce the damage of MRSA exotoxins to RBCs by 17.13%. Furthermore, excellent in vivo bacteria elimination and promoted wound healing were observed of RPTR-701Ns with a MRSA-infected mice model without causing toxicity. In summary, the novel delivery system provides a synergistic antibacterial treatment of both sustained release and bacterial toxins absorption, facilitating the incorporation of TR-701 into modern nanotechnology.

Download Full-text

Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles

European Journal of Pharmaceutics and Biopharmaceutics ◽

10.1016/j.ejpb.2014.06.020 ◽

2014 ◽

Vol 88 (2) ◽

pp. 529-538 ◽

Cited By ~ 45

Author(s):

Chuda Chittasupho ◽

Kriengsak Lirdprapamongkol ◽

Prartana Kewsuwan ◽

Narong Sarisuta

Keyword(s):

Lung Cancer ◽

Cancer Cells ◽

Targeted Delivery ◽

Plga Nanoparticles ◽

Lung Cancer Cells ◽

Cxcr4 Antagonist ◽

A549 Lung

Download Full-text

Multivesicular liposome: A lipid-based drug delivery system for efficient drug delivery

Current Pharmaceutical Design ◽

10.2174/1381612827666210830095941 ◽

2021 ◽

Vol 27 ◽

Author(s):

Bapi Gorain ◽

Bandar E. Al-Dhubiab ◽

Anroop Nair ◽

Prashant Kesharwani ◽

Manisha Pandey ◽

...

Keyword(s):

Drug Delivery ◽

Sustained Release ◽

Delivery System ◽

Targeted Delivery ◽

Drug Loading ◽

Therapeutic Agents ◽

Laboratory Research ◽

Efficacy And Safety ◽

Liposomal Delivery ◽

Proteins And Peptides

: The advancement of delivery tools for therapeutic agents has brought several novel formulations with increased drug loading, sustained release, targeted delivery, and prolonged efficacy. Amongst the several novel delivery approaches, multivesicular liposome has gained potential interest because this delivery system possesses the above advantages. In addition, this multivesicular liposomal delivery prevents degradation of the entrapped drug within the physiological environment while administered. The special structure of the vesicles allowed successful entrapment of hydrophobic and hydrophilic therapeutic agents, including proteins and peptides. Furthermore, this novel formulation could maintain the desired drug concentration in the plasma for a prolonged period, which helps to reduce the dosing frequencies, improve bioavailability, and safety. This tool could also provide stability of the formulation, and finally gaining patient compliance. Several multivesicular liposomes received approval for clinical research, while others are at different stages of laboratory research. In this review, we have focused on the preparation of multivesicular liposomes along with their application in different ailments for the improvement of the performance of the entrapped drug. Moreover, the challenges of delivering multivesicular vesicles have also been emphasized. Overall, it could be inferred that multivesicular liposomal delivery is a novel platform of advanced drug delivery with improved efficacy and safety.

Download Full-text

Remote-Controllable Bone-Targeted Delivery of Estradiol For the Treatment of Ovariectomy-Induced Osteoporosis in Rats

10.21203/rs.3.rs-628262/v1 ◽

2021 ◽

Author(s):

Dehao Fu ◽

Yuanyuan Guo ◽

Yongwei Liu ◽

Chen Shi ◽

Tingting Wu ◽

...

Keyword(s):

Particle Size ◽

Bone Tissue ◽

Targeted Delivery ◽

Hormone Replacement ◽

Plga Nanoparticles ◽

Raw 264.7 Cells ◽

Diffusion Method ◽

Tissue Destruction ◽

Trap 5B ◽

Post Menopausal

Abstract BackgroundOsteoporosis (OP) is a systemic skeletal disease marked by bone mass reduction and bone tissue destruction. Hormone replacement therapy is an effective treatment for post-menopausal OP, but estrogen has poor tissue selectivity and severe side effects.ResultsIn this study, we constructed a poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs)-based drug delivery system to co-load 17β estradiol (E2) and iron oxide (Fe3O4) together, modified with alendronate (AL) to achieve bone targeting and realize a magnetically remote-controllable drug release. The NPs were fabricated through the emulsion solvent diffusion method. The particle size was approximately 200 nm while the encapsulation efficiency of E2 was 58.34 ± 9.21%. The NPs were found to be spherical with a homogenous distribution of particle size. The NPs showed good stability, good biocompatibility, high encapsulation ability of E2 and excellent magnetic properties. The NPs could be effectively taken up by Raw 264.7 cells and were effective in enriching drugs in bone tissue. The co-loaded NPs exposed to an external magnetic field ameliorated OVX-induced bone loss through increased BV/TV, decreased Tb.N and Tb.Sp, improved bone strength, increased PINP and OC, and downregulated CTX and TRAP-5b. The haematological index and histopathological analyses displayed the NPs had less side effects on non-skeletal tissues.ConclusionsThis study presented a remote-controlled release system based on bone-targeted multifunctional NPs and a new potential approach to bone-targeted therapy of OP.

Download Full-text